something you want to know about SR9009

Description SR9009, which is currently under development at The Scripps Research

Institute (TSRI), increases the level of metabolic activity in skeletal

muscles of mice. Treated mice become lean, develop larger muscles and can

run much longer distances simply by taking SR9009, which mimics the effects

of aerobic exercise. If similar effects can be obtained in people, the

reversal of obesity, metabolic syndrome, and perhaps Type-II diabetes might

be the very welcome result. The drug was developed by Professor Thomas Burris, who found that it was

able to reduce obesity in populations of mice. It binds to and activates a

protein called Rev-ErbAa, which influences fat and sugar burning in the

liver, production of fat cells, and the body's inflammatory response. Reference If the effects of SR9009 on mice can safely be reproduced for people, the

new drug may offer new therapies for obesity and its companions, metabolic

syndrome and diabetes. Another area in which SR9009 or a similar drug may

confer substantial benefit is to offset the loss of general muscle

conditioning which occurs as a side effect of reduced activity caused by

illness and/or aging. People most likely to enjoy these benefits include

those suffering from severe arthritis, congestive heart failure, chronic

obstructive pulmonary disease (COPD), and other conditions that restrict

the ability to exercise.